Skip to main content
Top
Published in: Clinical and Experimental Nephrology 4/2011

01-08-2011 | Case Report

Renal failure caused by plasma cell infiltration in multiple myeloma

Authors: Shiho Hanawa, Tetsu Akimoto, Eisuke Uehara, Makoto Inoue, Toshimi Imai, Atsushi Kotoda, Hiromichi Yoshizawa, Tomohiro Matsuyama, Masuzu Ueda, Osamu Saito, Yoshitomo Hamano, Wako Yumura, Keiya Ozawa, Shigeaki Muto, Eiji Kusano

Published in: Clinical and Experimental Nephrology | Issue 4/2011

Login to get access

Abstract

We report on a case of severe renal failure in a 61-year-old female with multiple myeloma (MM). Two months prior to admission, the patient was diagnosed to have anemia and progressive renal failure associated with urinary Bence Jones protein and was referred to our hospital. A bone marrow biopsy revealed 40% plasma cells with κ light chain restriction. Thus, she was considered to have MM. A renal biopsy revealed neoplastic plasma cell infiltration within the kidney, moderate interstitial fibrosis, tubular atrophy, and punctate, electron-dense material along the peripheral capillary walls, tubular basement membrane, and in the interstitium of the kidney. This suggested that a combination of compression of the tubules and the microvasculature by the infiltrative process, and local light chain deposition-mediated tissue damage might be implicated in the development of renal failure in this patient. Despite a remission of bone marrow plasmacytosis with a bortezomib-based regimen, her renal function gradually deteriorated and a periodic hemodialysis program was finally required. Although the clinical impact of the direct kidney infiltration of neoplastic plasma cells on the longitudinal changes in renal function remains to be delineated, it is reasonable to consider that the infiltration of neoplastic plasma cells associated with local light chain depositions may result in irreversible renal injuries. Obviously, further studies and accumulation of additional experience with renal biopsy are required to better determine the precise and prognostic relationship between renal outcome and morphological alterations among MM patients with varying degrees of renal impairment.
Literature
1.
go back to reference Kapadia SB. Multiple myeloma: a clinicopathological study of 62 consecutively autopsied cases with multiple myeloma. Medicine. 1980;59:380–92.CrossRefPubMed Kapadia SB. Multiple myeloma: a clinicopathological study of 62 consecutively autopsied cases with multiple myeloma. Medicine. 1980;59:380–92.CrossRefPubMed
2.
go back to reference Oshima K, Kanda Y, Nannya Y, Kaneko M, Hamaki T, Suguro M, et al. Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma. Am J Hematol. 2001;67:1–5.CrossRefPubMed Oshima K, Kanda Y, Nannya Y, Kaneko M, Hamaki T, Suguro M, et al. Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma. Am J Hematol. 2001;67:1–5.CrossRefPubMed
3.
go back to reference Herrera GA, Joseph L, Gu X, Hough A, Barlogie B. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med. 2004;128:875–9.PubMed Herrera GA, Joseph L, Gu X, Hough A, Barlogie B. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med. 2004;128:875–9.PubMed
4.
go back to reference The kidney in multiple myeloma. West J Med. 1978;129:41–8. The kidney in multiple myeloma. West J Med. 1978;129:41–8.
5.
go back to reference Pasquali S, Zucchelli P, Casanova S, Cagnoli L, Confalonieri R, Pozzi C, et al. Renal histological lesions and clinical syndromes in multiple myeloma. Clin Nephrol. 1987;27:222–8.PubMed Pasquali S, Zucchelli P, Casanova S, Cagnoli L, Confalonieri R, Pozzi C, et al. Renal histological lesions and clinical syndromes in multiple myeloma. Clin Nephrol. 1987;27:222–8.PubMed
6.
go back to reference Lommatzsch SE, Bellizzi AM, Cathro HP, Rosner MH. Acute renal failure caused by renal infiltration by hematolymphoid malignancy. Ann Diag Pathol. 2006;10:230–4.CrossRef Lommatzsch SE, Bellizzi AM, Cathro HP, Rosner MH. Acute renal failure caused by renal infiltration by hematolymphoid malignancy. Ann Diag Pathol. 2006;10:230–4.CrossRef
7.
go back to reference Herrera GA, Picken MM. Renal diseases associated with plasma cell dyscrasias, amyloidosis, Waldenström macroglobulinemia, and cryoglobulinemic nephropathies. In: Jennette JC, Olson JL, Schwartz MM, Silvia FG, editors. Heptinstall’s pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 853–910. Herrera GA, Picken MM. Renal diseases associated with plasma cell dyscrasias, amyloidosis, Waldenström macroglobulinemia, and cryoglobulinemic nephropathies. In: Jennette JC, Olson JL, Schwartz MM, Silvia FG, editors. Heptinstall’s pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 853–910.
8.
go back to reference Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med. 1983;309:1543–6.CrossRefPubMed Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med. 1983;309:1543–6.CrossRefPubMed
9.
go back to reference Kyrtsonis MC, Maltezas D, Tzenou T, Koulieris E, Bradwell AR. Staging system and prognostic factors as a guide to therapeutic decisions in multiple myeloma. Semin Hematol. 2009;46:110–7.CrossRefPubMed Kyrtsonis MC, Maltezas D, Tzenou T, Koulieris E, Bradwell AR. Staging system and prognostic factors as a guide to therapeutic decisions in multiple myeloma. Semin Hematol. 2009;46:110–7.CrossRefPubMed
11.
go back to reference Pillon L, Sweeting RS, Arora A, Notkin A, Ballard HS, Wieczorek RL, et al. Approach to acute renal failure in biopsy proven myeloma cast nephropathy: is there still a role for plasmapheresis? Kidney Int. 2008;74:956–61.CrossRefPubMed Pillon L, Sweeting RS, Arora A, Notkin A, Ballard HS, Wieczorek RL, et al. Approach to acute renal failure in biopsy proven myeloma cast nephropathy: is there still a role for plasmapheresis? Kidney Int. 2008;74:956–61.CrossRefPubMed
12.
go back to reference Border WA, Cohen AH. Renal biopsy diagnosis of clinically silent multiple myeloma. Ann Int Med. 1980;93:43–6.CrossRefPubMed Border WA, Cohen AH. Renal biopsy diagnosis of clinically silent multiple myeloma. Ann Int Med. 1980;93:43–6.CrossRefPubMed
13.
go back to reference Hill GS, Morel-Maroger L, Méry JP, Brouet JC, Mignon F. Renal lesions in multiple myeloma: their relationship to associated protein abnormalities. Am J Kidney Dis. 1983;2:423–38.CrossRefPubMed Hill GS, Morel-Maroger L, Méry JP, Brouet JC, Mignon F. Renal lesions in multiple myeloma: their relationship to associated protein abnormalities. Am J Kidney Dis. 1983;2:423–38.CrossRefPubMed
14.
go back to reference Montseny JJ, Kleinknecht D, Meyrier A, Vanhille P, Simon P, Pruna A, et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant. 1998;13:1438–45.CrossRefPubMed Montseny JJ, Kleinknecht D, Meyrier A, Vanhille P, Simon P, Pruna A, et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant. 1998;13:1438–45.CrossRefPubMed
15.
go back to reference Laszik ZG, Silva FG. Hemolytic uremic syndrome, thrombotic thrombocytopenic perpura, and other thrombotic microangiopathies. In: Jennette JC, Olson JL, Schwartz MM, Silvia FG, editors. Heptinstall’s pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 701–64. Laszik ZG, Silva FG. Hemolytic uremic syndrome, thrombotic thrombocytopenic perpura, and other thrombotic microangiopathies. In: Jennette JC, Olson JL, Schwartz MM, Silvia FG, editors. Heptinstall’s pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 701–64.
16.
go back to reference Galani Z, Viniou N, Kyrtsonis MC, Sachanas S, Antoniou T, Dimopoulou MN, et al. Hepatic and renal plasma cell lesions in a patient with multiple myeloma in hematological remission. Anticancer Res. 2007;27:571–4.PubMed Galani Z, Viniou N, Kyrtsonis MC, Sachanas S, Antoniou T, Dimopoulou MN, et al. Hepatic and renal plasma cell lesions in a patient with multiple myeloma in hematological remission. Anticancer Res. 2007;27:571–4.PubMed
17.
go back to reference Pozzi C, D’Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis. 2003;42:1154–63.CrossRefPubMed Pozzi C, D’Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis. 2003;42:1154–63.CrossRefPubMed
18.
go back to reference Sellin L, Friedl C, Klein G, Waldherr R, Rump LC, Weiner SM. Acute renal failure due to a malignant lymphoma infiltration uncovered by renal biopsy. Nephrol Dial Transplant. 2004;19:2657–60.CrossRefPubMed Sellin L, Friedl C, Klein G, Waldherr R, Rump LC, Weiner SM. Acute renal failure due to a malignant lymphoma infiltration uncovered by renal biopsy. Nephrol Dial Transplant. 2004;19:2657–60.CrossRefPubMed
19.
go back to reference Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008;22:1485–93.CrossRefPubMed Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008;22:1485–93.CrossRefPubMed
20.
go back to reference Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889–93.CrossRefPubMed Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889–93.CrossRefPubMed
21.
go back to reference Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmprousi D, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 2007;92:546–9.CrossRefPubMed Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmprousi D, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 2007;92:546–9.CrossRefPubMed
22.
go back to reference Roussou M, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Grapsa I, et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res. 2010;34:1395–7.CrossRefPubMed Roussou M, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Grapsa I, et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res. 2010;34:1395–7.CrossRefPubMed
23.
go back to reference Morabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G, et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian myeloma network GIMEMA. Eur J Haematol. 2010;84:223–8.CrossRefPubMed Morabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G, et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian myeloma network GIMEMA. Eur J Haematol. 2010;84:223–8.CrossRefPubMed
24.
go back to reference Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol. 2009;4:745–54.CrossRefPubMedPubMedCentral Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol. 2009;4:745–54.CrossRefPubMedPubMedCentral
25.
go back to reference Blade RTJ, Lopez-Pedret ACJ, Rozman MC, Revert L. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol. 1995;91:854–9.CrossRefPubMed Blade RTJ, Lopez-Pedret ACJ, Rozman MC, Revert L. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol. 1995;91:854–9.CrossRefPubMed
26.
go back to reference Terpos E, Politou M, Rahemtulla A. Tumor lysis sundrome in multiple myeloma after bortezomib (VELCADE) administration. J Cancer Res Clin Oncol. 2004;130:623–5.CrossRefPubMed Terpos E, Politou M, Rahemtulla A. Tumor lysis sundrome in multiple myeloma after bortezomib (VELCADE) administration. J Cancer Res Clin Oncol. 2004;130:623–5.CrossRefPubMed
Metadata
Title
Renal failure caused by plasma cell infiltration in multiple myeloma
Authors
Shiho Hanawa
Tetsu Akimoto
Eisuke Uehara
Makoto Inoue
Toshimi Imai
Atsushi Kotoda
Hiromichi Yoshizawa
Tomohiro Matsuyama
Masuzu Ueda
Osamu Saito
Yoshitomo Hamano
Wako Yumura
Keiya Ozawa
Shigeaki Muto
Eiji Kusano
Publication date
01-08-2011
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 4/2011
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-011-0437-x

Other articles of this Issue 4/2011

Clinical and Experimental Nephrology 4/2011 Go to the issue

Editorial Announcement

A new journal: CEN Case Reports